Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Salix Pharmaceuticals (SLXP)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for SLXP as compared to
Top Competitors
Drug Related Products.
Drug Related Products
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS (
See all
)
Revenue
►
223M
AVG
Revenue
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
223M
AVG
EBITDA
►
-21.6M
LOW
Net Income
►
-47.1M
LOW
Revenue Growth
►
41.6%
VERY HIGH
Net Income Growth
►
-73.9%
LOW
Operating Margin
►
-19.6%
AVG
Net Margin
►
-21.1%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
0.645
AVG
Current Ratio
►
1.98
AVG
Quick Ratio
►
1.73
AVG
Interest Coverage Ratio
►
-9.60
LOW
Book Value Per Share
►
4.77
Cash Per Share
►
1.39
Loading...
STOCK SUMMARY
Open
Day Range
-
52 Week Range
-
Volume
Avg Volume (3 mo)
Shares Outstanding
Market Cap
VALUATION
Price to Earnings (P/E)
►
-24.7
Price to Book (P/B)
►
4.90
HIGH
Price to Sales (P/S)
►
5.21
HIGH
Return on Assets (ROA)
►
-10.5%
AVG
Return on Equity (ROE)
►
-19%
AVG
EV/EBITDA
►
-59.9
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
-19.9%
Net Insider Buying 6mo
-26.6%
Net Insider Buying 1yr
-14%
Held by insiders
2.3%
Held by institutions
19.8%